Mark Pykett, President of Boston Life Sciences, Inc.,
Rings The NASDAQ Stock Market Closing Bell

Wednesday, July 26, 2006
at NASDAQ's MarketSite
in New York City.

Boston Life Sciences, Inc.

Mark Pykett, President of Boston Life Sciences, Inc. (BLSI) presides over the closing bell.
Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials as an aid in the diagnosis of Parkinson's Disease and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine to promote functional recovery following stroke and spinal cord injury, a DAT blocker for the treatment of Parkinson's disease, oncomodulin for regeneration of the optic nerve and a second generation technetium-based molecular imaging agent for diagnosing Parkinson's Disease and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 7/26/2006 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Mark Pykett, President of Boston Life Sciences, Inc., rings the Closing Bell. These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.